Pegaptanib Sodium
Title: Pegaptanib Sodium
CAS Registry Number: 222716-86-1
Additional Names: PEG-t44-OMe
Manufacturers' Codes: EYE-001; NX-1838
Trademarks: Macugen (Eyetech)
Literature References: 2ยข-Fluoropyrimidine RNA aptamer to human VEGF165; composed of 28-mer oligonucleotide conjugated to 40 kDa polyethylene glycol moiety. Prepn: N. Janjic et al., WO 9818480; eidem, US 6168778 (1998, 2001 both to NeXstar Pharm.); and binding affinity studies: J. Ruckman et al., J. Biol. Chem. 273, 20556 (1998). Inhibition of in vitro VEGF-mediated responses: C. Bell et al., In Vitro Cell. Dev. Biol. Animal 35, 533 (1999). HPLC determn in plasma: C. E. Tucker et al., J. Chromatogr. B 732, 203 (1999). Pharmacokinetics: D. W. Drolet et al., Pharm. Res. 17, 1503 (2000). Pharmacology and clinical safety study: Eyetech Study Group, Retina 22, 143 (2002). Clinical study in age-related macular degeneration: E. S. Gragoudas et al., N. Engl. J. Med. 351, 2805 (2004). Review of development and therapeutic potential: S. A. Vinores, Curr. Opin. Mol. Ther. 5, 673-679 (2003); of clinical experience and safety in macular degeneration: A. A. Moshfeghi, C. A. Puliafito, Expert Opin. Invest. Drugs 14, 671-682 (2005).
Therap-Cat: In treatment of age-related macular degeneration and diabetic macular edema.
Keywords: Macular Degeneration Treatment.

Others monographs:
AlginBismuth NitrateSulfametroleDicyclohexylamine
Gallamine TriethiodideNaphthol Yellow SBinapacrylγ-Linolenic Acid
DibenzylamineSandaracAminochlorthenoxazinPipamperone
PlastoquinonesTebufenpyradCitric Acidd-Amyl Bromide
©2016 DrugLead US FDA&EMEA